Abstracts tagged "Disease Activity"

Abstract Number: 0357 • ACR Convergence 2023
Validation of the Juvenile Spondyloarthritis Disease Activity Index in a Prospective Clinical Trial Setting
Pamela F. Weiss¹, Nicolino Ruperto², Erhard Quebe-Fehling³, Alexis Shew⁴, Luminita Pricop⁵, Christelle Pieterse³ and Hermine Brunner⁶, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, St. Louis, MO, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
Background/Purpose: The juvenile spondyloarthritis disease activity index (JSpADA) is a disease activity assessment tool developed for children with juvenile psoriatic arthritis (JPsA) and enthesitis related…
Abstract Number: 0517 • ACR Convergence 2023
Which ASDAS Cut-Off Corresponds Best to Treatment Intensification in Patients with Axial Spondyloarthritis in Daily Practice?
Casper Webers¹, Rabab Nezam El-Din¹, Marin Been¹, Harald Vonkeman² and Astrid van Tubergen¹, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, ²Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands
Background/Purpose: In patients with axial spondyloarthritis (axSpA) and high disease activity (typically defined as Ankylosing Spondylitis Disease Activity Score [ASDAS]≥2.1), it is recommended to adapt…
Abstract Number: 0832 • ACR Convergence 2023
Cumulative Social Disadvantage Is Associated with Disease Activity and Functional Disability in Juvenile Idiopathic Arthritis: An Analysis of the CARRA Registry
William Soulsby, Erica Lawson, John Boscardin and Emily von scheven, University of California San Francisco, San Francisco, CA
Background/Purpose: The impact of race and social determinants of health (SDoH) on health outcomes in juvenile idiopathic arthritis (JIA) remains poorly understood. Prior disparities research…
Abstract Number: 1063 • ACR Convergence 2023
Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Jenny Li¹, Marie Hudson², Carrie Ye³, Janet Roberts⁴, Aurore Fifi-Mah⁵, May Choi⁵, Sabrina Hoa⁶, Thomas Appleton⁷, Janet Pope⁷, Nancy Maltez⁸, Lourdes Gonzalez Arreola⁹, Anthony Obrzut⁹ and Shahin Jamal¹⁰, ¹University of British Columbia, Vancouver, BC, Canada, ²McGill University, Montréal, QC, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷University of Western Ontario, London, ON, Canada, ⁸The Ottawa Hospital, Ottawa, ON, Canada, ⁹Arthritis Research Canada, Vancouver, BC, Canada, ¹⁰Vancouver Coastal Health, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy. Their use is complicated by development of immune-related adverse effects (irAEs), including rheumatic irAEs (Rh-irAE). Aging…
Abstract Number: 1361 • ACR Convergence 2023
Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Achieving remission is one of the treatment targets in the lupus care and it is also important in preventing the prevalence of adverse pregnancy…
Abstract Number: 1448 • ACR Convergence 2023
Association of Disease Activity and Anti-Double Stranded DNA Antibodies Titers with Echocardiographic Parameters in Systemic Lupus Erythematosus Patients
Natalia Guajardo-Jauregui¹, Iris Colunga², José Ramón Azpiri-López², Dionicio A. Galarza-Delgado², Jesus Alberto Cardenas-De la Garza³ and Rosa Arvizu-Rivera⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that involves the deposition of immunocomplexes on vital organs, including the heart. Cardiovascular disease is…
Abstract Number: 1905 • ACR Convergence 2023
Implementation of the Clinical Disease Activity Index to Optimize Treat-to-Target Management of Rheumatoid Arthritis at the University of North Carolina Hospitals Rheumatology Specialty Clinic
Rumey Ishizawar¹, Thuyvan Phan² and Steven Takacs³, ¹University of North Carolina at Chapel Hill, School of Medicine, Division of Rheumatology, Allergy, and Immunology, Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina Hospitals Department of Pharmacy, Apex, NC, ³University of North Carolina Faculty Physicians, Chapel Hill, NC
Background/Purpose: The 2021 American College of Rheumatology (ACR) guidelines for the treatment of rheumatoid arthritis (RA) recommend a treat-to-target approach to optimize clinical outcomes. This…
Abstract Number: 2264 • ACR Convergence 2023
Proposal for Defining Moderate and Severe Activity States in Systemic Lupus Erythematosus. Impact on Flares and Other Outcomes
Ivonne Lourdes Mamani Velarde¹, Iñigo Rúa-Figueroa², Sara García Pérez¹, Irene Altabás González³, CORAL Mourino Rodriguez⁴, Norman Jiménez⁵, JULIA MARTINEZ BARRIO⁶, Maria Galindo-Izquierdo⁷, Jaime Calvo- Alén⁸, Celia Eurasquin⁹, Belen Serrano Benavente¹⁰, Esther Uriarte Isacelaya¹¹, Eva Tomero Muriel¹², Mercedes Freire González¹³, Ricardo Blanco¹⁴, Eva Salgado-Pérez¹⁵, Paloma Vela¹⁶, Antonio Fernandez-Nebro¹⁷, Alejandro Olivé-Marqués¹⁸, Clara Sanguesa Gomez¹⁹, Javier Narvaez²⁰, Raúl Menor-Almagro²¹, Jose Rosas²², José Ángel Hernández Beriain²³, JAVIER MANERO²⁴, Elena Aurrecoechea Aguinaga²⁵, Oihane Ibarguengoitia-Barrena²⁶, Carlos Montilla-Morales²⁷, Gema Bonilla²⁸, Vicente Torrente-Segarra²⁹, Ana Paula Cacheda³⁰, Maria J. García-Villanueva³¹, Clara Moriano Morales³², Concepción Fito Manteca³³, Nuria Lozano Rivas³⁴, Cristina Bohórquez³⁵ and Jose-Maria Pego-Reigosa³⁶, ¹University Hospital of Vigo, Department of Rheumatology. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute (IISGS), Vigo, Spain, ²Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ³Department of Rheumatology, University Hospital of Vigo. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, ⁴Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁵IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁶Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁷Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁸Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁹Department of Rheumatology, Doctor Negrín University Hospital, Las Palmas de Gran Canaria, Spain, ¹⁰Rheumatology Department Hospital Gregorio Marañón, Madrid, Spain, ¹¹Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹²Rheumatology, Hospital La Princesa, Madrid, Spain, ¹³Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁵Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ¹⁶Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, ¹⁷Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁸Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁹Severo Ochoa Hospital, Madrid, Spain, ²⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ²¹Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ²²Department of Rheumatology, Hospital Villajoyosa, Alicante, Spain, ²³Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁴Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, ²⁵Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ²⁶Galdakao-Usansolo University Hospital, Bilbao, Spain, ²⁷Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ²⁸Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁹Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ³⁰Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, ³¹Hospital Ramón y Cajal, Madrid, Spain, ³²Rheumatology, Hospital Universitario de León, León, Spain, ³³Complejo Universitario de Navarra, Pamplona, Spain, ³⁴Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ³⁵Department of Rheumatology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain, ³⁶Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: In systemic lupus erythematosus (SLE), there is no definition of states of moderate and severe SLE activity. How these states may influence different disease…
Abstract Number: 2476 • ACR Convergence 2023
Defining Cutoffs for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score
Silvia Rosina¹, Ana Isabel Rebollo Gimenez², Letizia Tarantola¹, Yulia Vyzhga¹, Luca Carlini³, Elisa Patrone⁴, Maria Katsikas⁵, Claudia Saad-Magalhaes⁶, Dalia El-Ghoneimy⁷, Yasser El Miedany⁸, Raju Khubchandani⁹, Priyankar Pal¹⁰, Gabriele Simonini¹¹, Giovanni Filocamo¹², Maurizio Gattinara¹³, Fabrizio De Benedetti¹⁴, Davide Montin¹⁵, Adele Civino¹⁶, Muatasem Alsuweiti¹⁷, Valda Stenevicha¹⁸, Vyacheslav Chasnyk¹⁹, Ekaterina Alexeeva²⁰, Sulaiman Al-Mayouf²¹, Soamarat Vilayuk²², Angela Pistorio²³ and Angelo Ravelli²⁴, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ³IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, ⁴IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genova, Italy, ⁵Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, ⁶Sao Paulo State University, Botucatu, Brazil, ⁷PAIR Unit, Children's Hospital Ain Shams University, Cairo, Egypt, ⁸Ain Shams University, Italian Hospital St Abbassia, Cairo, Egypt, ⁹SRCC Childrens Hospital, Mumbai, India, ¹⁰Institute of Child Health, Pediatric Medicine, Kolkata, India, ¹¹Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy, ¹²Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Pediatric Rheumatology, Milan, Italy, ¹³Istituto Gaetano Pini, Divisione di Reumatologia, Milan, Italy, ¹⁴Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, ¹⁵Immunology and Rheumatology Unit, Regina Margherita Children Hospital, Turin, Italy, ¹⁶P.O. Vito Fazzi, Uo Pediatria - Sezione Reumatologia e Immunologia Pediatrica, Lecce, Italy, ¹⁷King Hussein Medical Center, Department of Pediatrics, Amman, Jordan, ¹⁸Department of Paediatrics, Riga Stradins University, Children University Hospital, Riga, Latvia, ¹⁹Saint-Petersburg State Pediatric Medical University, Pediatrics, Saint-Petersburg, Russia, ²⁰Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ²¹King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ²²Mahidol University Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand, ²³Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²⁴Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The systemic Juvenile Arthritis Disease Activity Score (sJADAS) is a composite disease activity (DA) score specifically validated for use in systemic JIA (sJIA), whose…
Abstract Number: 0365 • ACR Convergence 2023
Establishing a Multidisciplinary Registry for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Insights into Patient Outcomes and Management Challenges
Stacey Tarvin¹, Amy Rakestraw², Jessica Lee², N. Shaun Matthews³, Susan H. Ballinger² and Christina M. Sparks², ¹Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN, ³Indiana University School of Dentistry, Indianapolis, IN
Background/Purpose: Temporomandibular joint (TMJ) arthritis, a condition frequently overlooked in patients with JIA, can result in joint damage if not promptly treated. Such damage presents…
Abstract Number: 0520 • ACR Convergence 2023
How Do Early Disease Activity and Early Clinical Response Associate with Long-Term Outcomes with Ixekizumab in Radiographic Axial Spondyloarthritis?
Sofia Ramiro¹, Cedric Lukas², Louis Bessette³, Pendleton Wickersham⁴, Soyi Liu-Leage⁵, Tommaso Panni⁵, Rebecca Bolce⁵, Boris Janos⁵, Michael Nissen⁶ and James Cheng-Chung Wei⁷, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²CHU Montpellier, Montpellier, France, ³Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁴Arthritis Associates PA, San Antonio, TX, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Geneva University Hospitals, Geneva, Switzerland, ⁷Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan
Background/Purpose: The ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) advise that a patient be assessed for biological disease-modifying anti-rheumatic drug (bDMARD) treatment response…
Abstract Number: 0839 • ACR Convergence 2023
Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): The Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2a IRIS-RA Study
Peter C. Taylor¹, Georg Schett², Fowzia Ibrahim³, Bei Zhou⁴, Jocelyn H. Leu⁵, Sophia G. Liva⁵, Qingmin Wang⁵, Ricardo Rojo Cella⁵, Chetan S. Karyekar⁵ and Kaiyin Fei⁵, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ³Janssen Research & Development, LLC, High Wycombe, United Kingdom, ⁴Janssen Research & Development, LLC, Chesterbrook, PA, ⁵Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: RA is a chronic inflammatory disease associated with autoantibodies. Despite the use of targeted therapies, up to half of patients fail to achieve remission…
Abstract Number: 1075 • ACR Convergence 2023
Impact of Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Lourdes Gonzalez Arreola¹, Carrie Ye², Marie Hudson³, Janet Roberts⁴, Janet Pope⁵, Thomas Appleton⁵, Sabrina Hoa⁶, Aurore Fifi-Mah⁷, Nancy Maltez⁸, Alexandra Saltman⁹, Megan Himmel⁹, Ines Colmegna¹⁰, Alexandra Ladouceur¹¹, Anthony Obrzut¹, Jeremiah Tan¹², David Moon², Tatiana Nevskaya⁵, Emma Schmidt¹³, Lindsay Cho⁴, Nader Toban¹⁴ and Shahin Jamal¹⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³McGill University, Montréal, QC, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸The Ottawa Hospital, Ottawa, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ¹²Arthritis Research Canada, Vancouver, Canada, Vancouver, BC, Canada, ¹³University of British Columbia, Vancouver, BC, Canada, ¹⁴Centre Hospitalier de l'Université de Montréal, Dollard-des-Ormeaux, QC, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have changed the landscape of treatment for many cancers. However, most cancer clinical trials for ICI excluded patients with pre-existing…
Abstract Number: 1377 • ACR Convergence 2023
Characterization of Pulmonary Manifestations of Sjögren Syndrome: A Multicenter Retrospective Study
Loïc Meudec¹, Cindy Marques², Pierre-Antoine Juge³, Robin Dhote⁴, Anne-Laure Fauchais⁵, Emanuelle Dernis⁶, Olivier Vittecoq⁷, Alain SARAUX⁸, Jacques-Eric Gottenberg⁹, Eric Hachulla¹⁰, Véronique Le Guern¹¹, Philippe Dieudé¹², Marie-Pierre Debray¹³, Antoine Beurnier¹⁴, Raphaele Seror¹⁵, Xavier Mariette¹⁶ and Gaetane Nocturne¹⁷, ¹CHU Kremlin-Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France, ²CHU Pitié Salpétrière, Internal Medicine 1, Paris, France, ³Division of Rheumatology, Inflammation, and Immunity Brigham & Women’s Hospital, Boston, MA, ⁴Department of Internal Medicine, Centre Hospitalier Avicenne, Bobigny, France, ⁵Dupuytren Hospital, Limoges, France, ⁶CH Le Mans, Le Mans, France, ⁷CHU Rouen, Rheumatology, Rouen, France, ⁸CHU Brest, Brest, France, ⁹Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ¹⁰CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ¹¹APHP Hôpital Cochin, Paris, France, ¹²Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France, ¹³CHU Bichat, Radiology, Paris, France, ¹⁴CHU Kremlin-Bicêtre, Functional Explorations, Le Kremlin-Bicêtre, France, ¹⁵University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ¹⁶Université Paris-Saclay, Le Kremlin-Bicêtre, France, ¹⁷APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Sjögren disease (Sjo) is a systemic immune-related disease with pulmonary manifestations occurring in up to 16% of patients [1], including interstitial lung disease (SS-ILD)…
Abstract Number: 1451 • ACR Convergence 2023
Evaluation of Changes in SLE Patients’ Phenotype at Disease Onset, and Assessment of Disease Activity, Damage and Therapy at Diagnosis and During Follow up in the Last Forty Years: Preliminary Data of a Single Center Experience
Micaela Fredi¹, Silvia Ebe Lucia Della Pina¹, Claudia Barison¹, Chiara Orlandi¹, Marzia Tedeschi², Mai Chiara², Cecilia Nalli¹ and Franco Franceschini¹, ¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ²University of Brescia, Brescia, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with a high degree of variability at onset, which may make SLE diagnosis challenging, with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].